Rchr
J-GLOBAL ID:201801000712579305   Update date: Jun. 25, 2024

Sumi Takuya

スミ タクヤ | Sumi Takuya
Affiliation and department:
Research theme for competitive and other funds  (1):
  • 2021 - 2024 細胞の極性を制御する遺伝子の組織、個体での機能とその分子機構の解明
Papers (9):
  • Shotaro Harada, Yoshihisa Koyama, Takao Imai, Yoshichika Yoshioka, Takuya Sumi, Hidenori Inohara, Shoichi Shimada. A mouse model of autoimmune inner ear disease without endolymphatic hydrops. Biochimica et biophysica acta. Molecular basis of disease. 2024. 1870. 5. 167198-167198
  • Yoshihisa Koyama, Yuki Kobayashi, Ikuei Hirota, Yuanjie Sun, Iwao Ohtsu, Hiroe Imai, Yoshichika Yoshioka, Hiroto Yanagawa, Takuya Sumi, Hikaru Kobayashi, et al. A new therapy against ulcerative colitis via the intestine and brain using the Si-based agent. Scientific Reports. 2022. 12. 1
  • Miyuki Doi, Nanako Nakama, Takuya Sumi, Noriyoshi Usui, Shoichi Shimada. Prenatal methamphetamine exposure causes dysfunction in glucose metabolism and low birthweight. Frontiers in Endocrinology. 2022. 13
  • Yoshihisa Koyama, Yuki Kobayashi, Ikuei Hirota, Yuanjie Sun, Iwao Ohtsu, Hiroe Imai, Yoshichika Yoshioka, Hiroto Yanagawa, Takuya Sumi, Hikaru Kobayashi, et al. Author Correction: A new therapy against ulcerative colitis via the intestine and brain using the Si-based agent. Scientific reports. 2022. 12. 1. 15150-15150
  • Yukiko Nakamura, Takuya Sumi, Osamu Mitani, Takashi Okamoto, Erika Kubo, Kuniharu Masui, Makoto Kondo, Yoshihisa Koyama, Noriyoshi Usui, Shoichi Shimada. SR 57227A, a serotonin type-3 receptor agonist, as a candidate analgesic agent targeting nociplastic pain. Biochemical and Biophysical Research Communications. 2022. 622. 143-148
more...
MISC (2):
  • 鷲見拓哉, 小山佳久, 小山佳久, 島田昌一, 島田昌一. ストレス誘導型難聴モデルマウスの解析. 日本神経化学会大会抄録集(Web). 2022. 65th
  • 小山佳久, 小山佳久, 小林悠輝, 廣田郁詠, SUN Yuanjie, 大津厳生, 大津厳生, 今井裕恵, 吉岡芳親, 柳川博斗, et al. 潰瘍性大腸炎の新規治療薬の開発. 日本解剖学会総会・全国学術集会講演プログラム・抄録集. 2022. 127th
※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page